Skip To Main Content
For US Healthcare Professionals
FRANCHESCA, an MS Patient, using OCREVUS since 2017

INFUSION EXPERIENCE

OCREVUS is an infusion that is given every 6 months.*

OCREVUS is an infusion therapy—also known as IV therapy—that is given through an IV placed in your arm. Depending on what you and your doctor decide is right for you, you can receive your infusions at an infusion center, your doctor’s office, or at home. Watch this video to learn more about what to expect.

*First treatment will be split into 2, for a total of 3 treatments the first year.

What does an infusion appointment look like?

Hear from real people about their experiences and what to expect when you get an infusion.

Receiving your OCREVUS infusion.

Before your first infusion, your healthcare provider or nurse will review the process with you and answer any questions you may have. Then, while you’re receiving your infusion, your healthcare team will monitor you closely from start to finish to ensure your comfort or in case you have an infusion reaction.

Download the OCREVUS Infusion Checklist

Total appointment time for your infusion: 4-6 hours

OCREVUS® (ocrelizumab) pre-infusion illustration with doctor and patient

Pre-infusion: 30-60 minutes

  • Your healthcare team will check your vital signs, evaluate for active infections, and ask questions about your overall health
  • After your check-up, you may also be given medications, such as corticosteroids, an antihistamine, and antifever medication to help reduce possible infusion reactions
OCREVUS® (ocrelizumab) patient infusion experience illustration

During infusion: 2-4 hours*

  • You’ll be seated in a supportive chair with all your belongings
  • Be sure to have some entertainment and snacks on hand to pass the time
  • Once you’re settled, an IV infusion needle will be placed in your arm and connected to an infusion pump
  • If an infusion reaction occurs, your healthcare team may stop or slow the rate of your infusion
OCREVUS® (ocrelizumab) patient post-infusion experience illustration

Post-infusion: 1 hour

  • For at least 1 hour after your OCREVUS infusion, you will be monitored for any side effects or infusion reactions
  • It’s important to call your healthcare provider right away if you have any signs or symptoms up to 24 hours after your infusion. See side effects listed below for a list of possible infusion reactions

*The duration of an infusion could be longer if an infusion reaction occurs.

Get support at every step.

Once you have been prescribed OCREVUS, you can enroll in OCREVUS CONNECTS®. One of the resources this program provides is access to your personal team of Patient Navigators. Your Patient Navigators are available to work with you throughout your OCREVUS journey and can assist you and your healthcare provider in identifying an infusion site option that works best for you.

Your first year on OCREVUS

You will receive 3 infusions administered by a trained healthcare professional. Your first dose will be split into 2 infusions, 2 weeks apart. Each infusion will last about 2 hours and 30 minutes. Your third infusion will be 6 months later and will last between 2 to 4 hours.*

OCREVUS® (ocrelizumab) infusion frequency chart - year 1

Year 2 and beyond

You will receive 1 infusion every 6 months, each lasting between 2 to 4 hours.*

OCREVUS® (ocrelizumab) infusion frequency chart - after year 1

*The duration of an infusion could be longer if an infusion reaction occurs.

You may be able to receive a shorter, 2-hour* infusion.

It’s the same dose of OCREVUS—and if you haven’t experienced any serious infusion reactions during your first 2 infusions, a shorter infusion option is available. In the trial that led to FDA approval of OCREVUS 2-hour infusions, serious infusion reactions included those that required hospitalization or were life-threatening. 

Ask your doctor if the shorter, 2-hour OCREVUS infusion option is right for you. 

*Your 2-hour infusion does not include pre-infusion medication and post-infusion observation time. The duration of an infusion could be longer if an infusion reaction occurs.

I'm glad my nurse told me about the 2-hour infusion. It's the same medication, just given faster. – a quote from ALEX, using OCREVUS since 2019

Make sure you understand the possible side effects.

Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. Most infusion reactions are mild to moderate, and treatable with infusion adjustments and medicines.* Post-infusion, you will be monitored for at least 1 hour for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you experience any reactions up to 24 hours after your infusion.

Infusion Reactions May Include
  • itchy skin
  • rash
  • hives
  • tiredness
  • coughing or wheezing
  • trouble breathing
  • throat irritation or pain
  • feeling faint
  • fever

 

 

  • redness on your face (flushing)
  • nausea
  • headache
  • swelling of the throat
  • dizziness
  • shortness of breath
  • fatigue
  • fast heart beat

 

 

*These findings were learned from relapsing MS studies (Study 1 and Study 2) and are comparable with rates seen in the PPMS study (Study 3).

PASTELL, an MS patient, using OCREVUS since 2018


Feel supported along your journey.

Call OCREVUS CONNECTS® at 1-844-OCREVUS. We’re happy to answer all your questions, from insurance and payment options to what to expect at an infusion. This no-cost service is available Monday through Friday, 9 AM to 8 PM ET, in English and Spanish.
OCREVUS CONNECTS®

Important Safety Information & Indications

What is OCREVUS?

OCREVUS is a prescription medicine used to treat:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults.

It is not known if OCREVUS is safe and effective in children.

Who should not receive OCREVUS?

Do not receive OCREVUS if you have an active hepatitis B virus (HBV) infection.

Do not receive OCREVUS if you have had a life-threatening allergic reaction to OCREVUS. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or any of its ingredients in the past.

What is the most important information I should know about OCREVUS?

OCREVUS can cause serious side effects, including:

  • Infusion reactions: Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms:
    • itchy skin
    • rash
    • hives
    • tiredness
    • coughing or wheezing
    • trouble breathing
    • throat irritation or pain
    • feeling faint
    • fever
    • redness on your face (flushing)
    • nausea
    • headache
    • swelling of the throat
    • dizziness
    • shortness of breath
    • fatigue
    • fast heart beat

These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

  • Infection:
    • Infections are a common side effect. OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with OCREVUS, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS until your infection is gone.
    • Hepatitis B virus (HBV) reactivation: Before starting treatment with OCREVUS, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS.
    • Weakened immune system: OCREVUS taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
  • Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability, and has been reported with OCREVUS. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:
    • thinking        
    • eyesight
    • strength
    • balance
    • weakness on 1 side of your body
    • using your arms or legs
  • Decreased immunoglobulins: OCREVUS may cause a decrease in some types of immunoglobulins. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving OCREVUS, tell your healthcare provider about all of your medical conditions, including if you:

  • have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS.
  • have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have a history of inflammatory bowel disease or colitis.
  • have had a recent vaccination or are scheduled to receive any vaccinations. 
    • You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS. You should not receive ‘live’ or ‘live attenuated’ vaccines while you are being treated with OCREVUS and until your healthcare provider tells you that your immune system is no longer weakened.
    • When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS, talk to your healthcare provider.
    • If you have a baby and you received OCREVUS during your pregnancy, it is important to tell your baby’s healthcare provider about receiving OCREVUS so they can decide when your baby should be vaccinated.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and for 6 months after your last infusion of OCREVUS. Talk with your healthcare provider about what birth control method is right for you during this time.
  • are breastfeeding or plan to breastfeed. It is not known if OCREVUS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of OCREVUS?

OCREVUS may cause serious side effects, including:

  • Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer.
  • Inflammation of the colon, or colitis: Tell your healthcare provider if you have any symptoms of colitis, such as:
    • Diarrhea (loose stools) or more frequent bowel movements than usual
    • Stools that are black, tarry, sticky or have blood or mucus
    • Severe stomach-area (abdomen) pain or tenderness

These are not all the possible side effects of OCREVUS.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (888) 835-2555.

For more information, go to www.OCREVUS.com or call 1-844-627-3887.

Please see additional Important Safety Information throughout and click here for full Prescribing Information and Medication Guide.

    • Stuifbergen A, Becker H, Phillips C, Horton S, Morrison J, Perez F. Experiences of African American Women with Multiple Sclerosis. Int J MS Care. 2021;23(2):59-65.

      Stuifbergen A, Becker H, Phillips C, Horton S, Morrison J, Perez F. Experiences of African American Women with Multiple Sclerosis. Int J MS Care. 2021;23(2):59-65.

    • Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022;98(18):e1818-e1827.

      Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022;98(18):e1818-e1827.

    • Okai AF, Howard AM, Williams MJ, et al. Advancing Care and Outcomes for African American Patients With Multiple Sclerosis. Neurology. 2022;98(24):1015​-1020.

      Okai AF, Howard AM, Williams MJ, et al. Advancing Care and Outcomes for African American Patients With Multiple Sclerosis. Neurology. 2022;98(24):1015​-1020.

    • Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler. 2020;26(5):561​-567.

      Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler. 2020;26(5):561​-567.

    • Ingram M, Leih R, Adkins A, Sonmez E, Yetman E. Health Disparities, Transportation Equity and Complete Streets: a Case Study of a Policy Development Process through the Lens of Critical Race Theory. J Urban Health. 2020;97(6):876​-886.

      Ingram M, Leih R, Adkins A, Sonmez E, Yetman E. Health Disparities, Transportation Equity and Complete Streets: a Case Study of a Policy Development Process through the Lens of Critical Race Theory. J Urban Health. 2020;97(6):876​-886.

    • Sohn H. Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage over the Life-Course. Popul Res Policy Rev. 2017;36(2):181​-201.

      Sohn H. Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage over the Life-Course. Popul Res Policy Rev. 2017;36(2):181​-201.

    • Taylor J. Racism, Inequality, and Health Care for African Americans. The Century Foundation. December 19, 2019. Accessed April 16, 2023. https://tcf.org/content/report/racism-inequality-health-care-african-americans.

      Taylor J. Racism, Inequality, and Health Care for African Americans. The Century Foundation. December 19, 2019. Accessed April 16, 2023. https://tcf.org/content/report/racism-inequality-health-care-african-americans.